Partner Content Partner Content MHRA, Pfizer, Autolus and Tusk Theraputics Sign Up for Immun... MHRA, Pfizer & Autolus Sign Up for Immuno-Oncology 2018
Partner Content Partner Content Less than 4 Weeks until Immuno-Therapy Experts Gather at the... Less than 4 Weeks until Immuno-Oncology Conference
Partner Content Partner Content Invitation from Chair of this year’s Immuno-Oncology Confere... Invitation from Chair of Immuno-Oncology Conference
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.